Confused about how the Medicare GLP-1 Bridge works in 2026? You’re not alone. The Medicare GLP-1 Bridge is a new, time-limited program that can cap certain GLP-1 weight-loss medicines at $50 per month, but the rules for eligibility, prior authorization, and drug lists are very specific.

Senior woman meeting with an insurance advisor at a kitchen table, reviewing Medicare documents with a laptop and prescription bottles nearby
Senior woman meeting with an insurance advisor at a kitchen table, reviewing Medicare documents with a laptop and prescription bottles nearby

What is the Medicare GLP-1 Bridge in 2026–2027, and why did CMS create it?

The Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge on July 1, 2026 to provide eligible Medicare Part D beneficiaries temporary access to select GLP-1 drugs for weight management at a flat $50 monthly copay. The demonstration now runs from July 1, 2026 through December 31, 2027 and operates outside the normal Part D payment flow.

Because it sits outside the standard Part D benefit, the $50 copay doesn’t count toward TrOOP or your Part D deductible, and Low-Income Subsidy (Extra Help) doesn’t reduce that copay. CMS uses a single central processor to handle prior authorization, claims, and pharmacy payments.

Who is eligible in 2026—and who isn’t?

You must have Medicare Part D coverage (through a standalone Part D plan or a Medicare Advantage plan with drug coverage) and meet clinical criteria based on body mass index (BMI) and certain conditions. Eligible paths include: BMI ≥35; BMI 30–34.9 with HFpEF, uncontrolled hypertension, or CKD stage 3a+; or BMI 27–29.9 with prediabetes or a history of heart attack, stroke, or symptomatic PAD.

You’re not eligible for the Medicare GLP-1 Bridge if you already receive GLP-1 drugs through your Part D plan or if you’re using a GLP-1 for Part D–covered indications like type 2 diabetes, moderate-to-severe sleep apnea, or MASH with moderate to advanced fibrosis—those are handled by your plan, not the Bridge.

Which GLP-1 medications are on the Medicare GLP-1 Bridge drug list in 2026?

As of July 2026, the Medicare GLP-1 Bridge covers Foundayo (tablets), Wegovy (injections and tablets), and Zepbound (KwikPen only) when prescribed for weight reduction and maintenance in combination with lifestyle modification. Single-dose Zepbound vials and single-dose pens are excluded. CMS notes the KwikPen-only limitation and that Foundayo was added following FDA approval; specific NDCs are published by CMS.

If your prescription is written for a non-eligible formulation or NDC, the pharmacy may receive a reject requiring the prescriber to rewrite the prescription for an eligible product. CMS provides a pharmacy reject code reference and NDC lists to resolve these issues.

How does prior authorization work under the Medicare GLP-1 Bridge?

For most members, a pharmacy will first try to process your prescription under the Bridge. If the system flags the need, the pharmacy sends a prior authorization request to your prescriber electronically or by fax; decisions are generally communicated within about 72 hours. There’s no formal appeals process for denials, but prescribers may resubmit with corrected or additional information.

Important: before your prescriber can submit the authorization, there must be a denied pharmacy claim to the Bridge BIN/PCN (BIN 028918, PCN MEDDGLP1BR). Prescribers can submit electronically (CoverMyMeds) or by fax using CMS’s three-page PA form that also documents BMI and clinical criteria.

What will you pay in 2026, and how do refills work?

Approved beneficiaries pay a flat $50 monthly copayment for a 28- or 30‑day supply. Refills and dose changes on the same GLP-1 don’t require a new authorization, and approvals remain valid through December 31, 2027. The $50 won’t show on your Part D EOB, won’t count toward your deductible or out-of-pocket cap, and Extra Help won’t lower it.

CMS indicates the Bridge is the primary payer and doesn’t coordinate benefits; coupons and discount cards can’t be applied. For travel, pharmacies may process limited vacation overrides; lost or stolen medication overrides aren’t available.

How do Part D plans and Medicare Advantage plans fit in during 2026?

Eligible Part D beneficiaries in standalone PDPs or Medicare Advantage HMO/PPO plans with drug coverage (including SNPs, EGWPs, and LI NET) can use the Medicare GLP-1 Bridge if they meet the clinical criteria and the drug is prescribed for weight management—not for a Part D–covered indication. Plan networks don’t determine Bridge eligibility, but your own plan still handles GLP-1s when used for covered conditions like type 2 diabetes or sleep apnea.

Behind the scenes, CMS uses a central processor (Humana, via the LI NET infrastructure) and has negotiated a $245 net price per monthly supply with participating manufacturers for drugs furnished under the Bridge, separate from your plan’s benefit.

Step-by-step: How North Carolina beneficiaries can coordinate with prescribers and Part D plans in 2026

  • Confirm you have Medicare Part D (standalone PDP or MA-PD) and meet the BMI/clinical criteria for the Medicare GLP-1 Bridge.
  • Talk with your prescriber about Foundayo tablets, Wegovy (injection or tablet), or Zepbound KwikPen for weight management alongside diet and activity; your prescriber must attest to lifestyle support.
  • Use a pharmacy that can process Bridge claims; they’ll submit first to the Bridge BIN/PCN and, if prompted, request prior authorization from your prescriber electronically or by fax.
  • Ensure the prescription matches an eligible NDC (all Wegovy forms, all Foundayo; Zepbound KwikPen only). If the claim rejects for product not covered, ask your prescriber to rewrite with an eligible NDC.
  • Watch for your Medicare letter confirming Bridge coverage, then pick up your 28–30 day supply for $50.
  • If you have a Part D–covered indication (for example, type 2 diabetes or moderate-to-severe sleep apnea), continue through your Part D plan—not the Bridge.
A pharmacist at a Charlotte, NC retail counter scanning a prescription with shelves of medications in the background
A pharmacist at a Charlotte, NC retail counter scanning a prescription with shelves of medications in the background

What are the most common drug-list and paperwork snags we’re seeing in July 2026—and how to avoid them?

  • Wrong Zepbound device: Only KwikPen is on the Medicare GLP-1 Bridge; single-dose vials and pens will be rejected. Ask for the KwikPen specifically.
  • Missing first-step claim: A denied claim to BIN 028918/PCN MEDDGLP1BR must precede the prior authorization. Remind the pharmacy and prescriber of this sequence.
  • Formulary confusion: If your diagnosis makes GLP-1s Part D–coverable (e.g., type 2 diabetes), your Part D plan handles it—not the Bridge—so send PA to the plan.
  • NDC mismatch: Prescriptions must use an eligible NDC from CMS’s list; otherwise, pharmacies may receive a “product not covered” reject.

Does the Medicare GLP-1 Bridge change anything about my 2026 Part D costs or out-of-pocket cap?

No. Because the Medicare GLP-1 Bridge sits outside the Part D benefit, your $50 monthly payment doesn’t count toward your Part D deductible, True Out-of-Pocket (TrOOP), or annual cap, and it won’t appear on your EOB or MSN. Extra Help doesn’t apply to the Bridge copay.

Does the Medicare GLP-1 Bridge change anything about my 2026 Part D costs or out-of-pocket cap
Does the Medicare GLP-1 Bridge change anything about my 2026 Part D costs or out-of-pocket cap

What if I’m traveling from Charlotte in late 2026—can I get an early refill?

CMS allows pharmacies to apply a vacation override at the point of sale for eligible fills. However, overrides aren’t available for lost or stolen medication, and 60- or 90-day supplies aren’t permitted under the Bridge.

2026 Medicare GLP-1 Bridge FAQs

When did the Medicare GLP-1 Bridge start, and when does it end?

The demonstration began July 1, 2026, and continues through December 31, 2027.

Which Medicare plan types are eligible?

Beneficiaries with standalone PDPs and Medicare Advantage plans that include drug coverage (HMO, HMOPOS, Local/Regional PPO) are eligible, as are SNPs, EGWPs, and LI NET members—subject to clinical criteria and weight-management use.

What’s the 2026 copayment and does “$50 monthly” vary by income?

The Bridge sets a flat, $50 monthly copayment for a one‑month supply (28 or 30 days) regardless of income, and it doesn’t apply to your Part D spending totals.

Do I need to “submit a prior authorization request,” or does my doctor do it?

Your prescriber submits the prior authorization—often after the pharmacy initiates it electronically. If you don’t see movement within 72 hours, your prescriber can fax CMS’s PA form directly.

Which GLP-1 drugs are covered in 2026?

Foundayo (tablet), Wegovy (injection or tablet), and Zepbound (KwikPen only); Zepbound vials and single‑dose pens aren’t covered. Drug and NDC lists can be updated by CMS.

What if I’m already on a GLP-1 through my Part D plan?

You should continue through your Part D plan; the Bridge is not available to people who already receive GLP-1 coverage through their Part D benefit.

Will my prescriber need to document lifestyle changes?

Yes. CMS requires your provider to certify that you’re using the GLP-1 medication as part of a lifestyle program emphasizing nutrition and physical activity, unless activity isn’t clinically appropriate.

Can I appeal if I’m denied?

There’s no formal appeals process under the Bridge, but prescribers can resubmit the authorization with corrected or additional information.

Why is the Bridge separate from Part D in 2026?

CMS structured the demonstration to expand short‑term access to certain GLP‑1s for weight management and gather data while the agency prepares broader affordability efforts (such as the BALANCE model). A central processor handles operations outside Part D’s normal risk and payment flow.

Practical example for 2026: How this works for a Charlotte beneficiary

A 68‑year‑old Charlotte resident with BMI 33 and uncontrolled hypertension discusses Wegovy with her primary care provider. The pharmacy submits a claim via the Bridge; a PA request is routed to the prescriber, who confirms BMI, hypertension, and lifestyle program participation. Within 72 hours the PA is approved; she pays $50 for a 28‑day supply and schedules follow-up for dose titration. Refills remain approved through December 31, 2027 as long as she stays on the same drug.

How Safeguard Benefit Services supports North Carolina Medicare members in 2026

Understanding the Medicare GLP-1 Bridge is only one piece of your 2026 Medicare strategy—especially if you’re comparing Medicare Advantage HMO vs. PPO networks, reviewing your Part D plan’s formulary for other prescriptions, or coordinating with prescribers across Charlotte’s health systems. Our licensed, independent North Carolina agents walk you through eligibility, coordinate with your doctor and pharmacy on prior authorization logistics, and help you avoid coverage gaps when Part D vs. Bridge rules overlap.

If you think you may qualify—or if a pharmacy rejected your GLP‑1 due to device or NDC mismatches—reach out to Safeguard Benefit Services for personalized, no‑pressure guidance and plan comparisons. Visit safeguardbenefitservices.com to schedule a conversation that fits your timeline.

Important sources and updates

  • CMS’s Medicare GLP‑1 Bridge page (program dates, $50 copay, operations outside Part D, central processor).
  • Medicare.gov “Weight loss drugs” (eligibility criteria, costs, letters, provider and lifestyle requirements).
  • CMS Prior Authorization form (BIN/PCN, PA steps, clinical questions).
  • CMS Information for Pharmacies/Providers/Part D Plans (drug list by brand/form, NDCs, refill rules, vacation overrides, $245 net price, plan interactions).
  • CMS Innovation Center BALANCE model insight (context for 2026–2027 transition).

Have questions about Medicare in 2026 beyond GLP‑1s?

Whether you’re evaluating Medicare Part D drug coverage, comparing Medicare Advantage plans in Mecklenburg County, or deciding if Medigap is right for you, Safeguard Benefit Services can help you make confident, compliant choices that fit your doctors and prescriptions.

Get one‑on‑one help today

Ready to check your 2026 Medicare GLP‑1 Bridge eligibility, coordinate prior authorization with your prescriber, and verify how your Part D plan handles your other medications? Contact Safeguard Benefit Services at safeguardbenefitservices.com for a friendly, local review and personalized next steps.

Professional disclaimer

This article is for educational purposes only and does not constitute medical, legal, or financial advice. Medicare rules and drug lists can change during 2026–2027; always confirm specifics with your prescriber, your Part D or Medicare Advantage plan, and Medicare (1‑800‑MEDICARE). Safeguard Benefit Services is an independent insurance agency serving North Carolina Medicare beneficiaries.

Sources